These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 20008209)

  • 1. Antiplatelet agents.
    Varon D; Spectre G
    Hematology Am Soc Hematol Educ Program; 2009; ():267-72. PubMed ID: 20008209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frontiers in platelet inhibition.
    Varon D; Shai E; Spectre G
    Discov Med; 2009 Dec; 8(43):242-6. PubMed ID: 20040278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiplatelet agents.
    Cattaneo M
    Hematol J; 2004; 5 Suppl 3():S170-4. PubMed ID: 15190302
    [No Abstract]   [Full Text] [Related]  

  • 4. Dual antiplatelet therapy for coronary stenting: a clear path for a research agenda.
    Leopold JA; Antman EM
    Circulation; 2005 Mar; 111(9):1097-9. PubMed ID: 15753225
    [No Abstract]   [Full Text] [Related]  

  • 5. Optimizing platelet P2Y12 inhibition for patients undergoing PCI.
    Steinhubl S; Roe MT
    Cardiovasc Drug Rev; 2007; 25(2):188-203. PubMed ID: 17614940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging oral antiplatelet therapies for acute coronary syndromes.
    Pollack CV
    Hosp Pract (1995); 2010 Nov; 38(4):29-37. PubMed ID: 21068524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet function testing and implications for clinical practice.
    Collet JP; Montalescot G
    J Cardiovasc Pharmacol Ther; 2009 Sep; 14(3):157-69. PubMed ID: 19721130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiplatelet agents and arterial thrombosis.
    Billett HH
    Cardiol Clin; 2008 May; 26(2):189-201, vi. PubMed ID: 18406994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advance in antiplatelet therapy: the mechanisms, evidence and approach to the problems.
    Horiuchi H
    Ann Med; 2006; 38(3):162-72. PubMed ID: 16720431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologists.
    Angiolillo DJ; Suryadevara S; Capranzano P; Zenni MZ; Guzman LA; Bass TA
    Catheter Cardiovasc Interv; 2009 Jan; 73(1):1-14. PubMed ID: 19089929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiplatelet agents in stroke prevention. combination therapy: present and future.
    Weksler BB
    Cerebrovasc Dis; 2000; 10 Suppl 5():41-8. PubMed ID: 11096182
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study.
    Cuisset T; Frere C; Quilici J; Morange PE; Mouret JP; Bali L; Moro PJ; Lambert M; Alessi MC; Bonnet JL
    JACC Cardiovasc Interv; 2008 Dec; 1(6):649-53. PubMed ID: 19463379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acute and long-term antiplatelet therapy.
    Papathanasiou AI; Goudevenos JA; Mikhailidis DP; Tselepis AD
    Drugs Today (Barc); 2008 May; 44(5):331-52. PubMed ID: 18548136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The future of platelet function testing to guide therapy in clopidogrel low and enhanced responders.
    Bernlochner I; Byrne RA; Kastrati A; Sibbing D
    Expert Rev Cardiovasc Ther; 2011 Aug; 9(8):999-1014. PubMed ID: 21878045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
    Capranzano P; Mehran R; Tamburino C; Stone GW; Dangas G
    Hosp Pract (1995); 2010 Nov; 38(4):38-43. PubMed ID: 21068525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet monitoring for PCI: is it really necessary?
    Tantry US; Gurbel PA
    Hamostaseologie; 2009 Nov; 29(4):368-75. PubMed ID: 19882080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of new P2Y12 inhibitors: selection of P2Y12 inhibitors in clinical practice.
    Golino P
    J Cardiovasc Med (Hagerstown); 2013 Dec; 14 Suppl 1():S22-30. PubMed ID: 24378838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
    Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
    Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aspirin and clopidogrel: a sweeping combination in cardiology.
    Manolis AS; Tzeis S; Andrikopoulos G; Koulouris S; Melita H
    Curr Med Chem Cardiovasc Hematol Agents; 2005 Jul; 3(3):203-19. PubMed ID: 15974885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual antiplatelet response during PCI: VerifyNow P2Y12 predicts myocardial necrosis and thromboxane B2 generation confirms wide variation in aspirin response.
    Good RI; McGarrity A; James TE; Miller H; McConnachie A; Goodall AH; Oldroyd KG
    Thromb Res; 2015 Jun; 135(6):1140-6. PubMed ID: 25746368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.